Phase 2 Evidence and Impact Analysis
Batch notes: 44 articles reviewed. All are abstract-only or title-only; no full texts accessed. All
classification_confidencevalues are medium (except Article 44, which is low). Scores are applied conservatively throughout. Several articles contain metadata inconsistencies from Phase 1 (e.g., a narrative review labeled "Randomized controlled trial" for Article 2; a lab study labeled "diagnostic validation" for several entries) — these are flagged inline and scores adjusted accordingly.
Article 1 — Alhajlah (2026) — cfDNA NIPT systematic review
PMID: 42677308 | Systematic Review | Early Detection | 🟢
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | cfDNA-NIPT is well-established; this is a confirmatory systematic review, not a novel finding |
| Clinical Relevance | 7 | NIPT is widely used in prenatal care; systematic evidence synthesis directly informs clinical guidelines |
| Population Reach | 8 | Prenatal screening affects millions of pregnancies annually worldwide |
| Implementation Speed | 8 | Technology is already in clinical use; review may update clinical protocols |
| Evidence Strength | 7 | Systematic review design is strong, but abstract-only limits full quality assessment |
Key quantitative result: Not reported in abstract excerpt. External validation: Systematic review synthesizes existing validated data. Main limitation: Abstract-only access; DOI suggests possible 2019 vintage paper newly indexed — publication date discrepancy warrants caution. Equity implications: NIPT access is inequitable globally; high-income countries benefit most. Low-resource settings remain underserved. Evidence Maturity: Validated ✓
Article 2 — Zhou et al. (2026) — Retinoblastoma precision review
PMID: 42679926 | Review (mislabeled RCT in metadata) | Treatment Innovation | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Synthesizes recent molecular oncology advances; eye-preserving therapy angle is meaningful |
| Clinical Relevance | 6 | Rare pediatric cancer with high unmet need; directly informs clinical management |
| Population Reach | 4 | Rare disease (global incidence ~8,000 children/year); high impact within affected population |
| Implementation Speed | 5 | Some strategies already in practice; others remain emerging |
| Evidence Strength | 4 | Narrative/comprehensive review; abstract-only; metadata error (labeled RCT) reduces confidence |
Key quantitative result: Not reported. External validation: Review summarizes existing evidence; no new primary data. Main limitation: Metadata mislabeled as RCT; abstract-only; no quantitative outcomes presented. Equity implications: Children in low-income countries still frequently undergo enucleation due to lack of access to intra-arterial chemotherapy. Evidence Maturity: Revised to Exploratory-to-Validated (depending on specific claim within review)
Article 3 — Long et al. (2026) — EfficientNet-B0 WBC scattergram AI
PMID: 42675854 | Lab/Observational Study | Early Detection | 🟢
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Applying EfficientNet to WBC-Diff scattergrams is a meaningful workflow innovation |
| Clinical Relevance | 5 | Useful for hematology lab triage; indirect patient benefit at this stage |
| Population Reach | 6 | WBC-Diff is ubiquitous; if validated, could affect millions of routine CBCs |
| Implementation Speed | 4 | Promising but requires prospective validation before deployment |
| Evidence Strength | 4 | Exploratory lab study; abstract-only; no prospective clinical validation reported |
Key quantitative result: Not reported in abstract. External validation: None reported. Main limitation: Single-center lab study; no external validation cohort; clinical performance metrics (sensitivity/specificity) not available from abstract. Equity implications: If deployed on existing analyzers at low cost, could benefit resource-limited labs globally. Evidence Maturity: Exploratory ✓
Article 4 — Singh & Pandey (2026) — Hypoxia ncRNA OSCC liquid biopsy
PMID: 42677123 | Review (mislabeled "Clinical trial" in metadata) | Early Detection | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | HIF-driven ncRNA signatures in OSCC liquid biopsy is an active but not yet mature area |
| Clinical Relevance | 4 | Preclinical/early conceptual; no validated clinical tool yet |
| Population Reach | 5 | OSCC affects ~350,000 new cases/year globally; late diagnosis is a genuine problem |
| Implementation Speed | 2 | Requires extensive clinical validation before any clinical use |
| Evidence Strength | 3 | Review article; DOI resolves to a Science paper which does not match (metadata inconsistency); abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Significant metadata errors (DOI mismatch, study design mislabeled). Conceptual review; no clinical data presented. Equity implications: OSCC disproportionately affects low-income populations with tobacco/betel nut exposure in South/Southeast Asia. Evidence Maturity: Revised to Exploratory
Article 5 — Henry et al. (2026) — Biallelic RNU2-2 epileptic encephalopathy
PMID: 42678714 | Diagnostic Validation Study | Genomics/Precision Medicine | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Biallelic RNU2-2 as a cause of DEE is recently described; characterization adds meaningful diagnostic value |
| Clinical Relevance | 7 | Directly resolves previously "unsolved" genetic epilepsy cases; changes diagnostic pathway |
| Population Reach | 4 | Rare disease; high impact for affected children and families |
| Implementation Speed | 5 | WGS is increasingly available; adding RNU2-2 to analysis pipelines is feasible |
| Evidence Strength | 5 | Diagnostic validation cohort; abstract-only; sample size not reported |
Key quantitative result: Not reported from abstract. External validation: Multicenter implied by author list; not confirmed. Main limitation: Abstract-only; sample size unknown; rare disease limits statistical power. Equity implications: Benefits children in settings with access to WGS; globally inequitable access to genomic diagnostics. Evidence Maturity: Validated ✓
Article 6 — Luković et al. (2026) — Dinuclear Platinum(II) complexes
PMID: 42679155 | Lab Study | Preclinical Drug Development | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Novel dinuclear Pt(II) architecture with dual DNA/albumin targeting is chemically interesting |
| Clinical Relevance | 2 | Purely preclinical; no human or animal efficacy data reported |
| Population Reach | 3 | Broad oncology relevance if developed, but far from clinical use |
| Implementation Speed | 1 | Early-stage synthesis; years from any clinical application |
| Evidence Strength | 3 | Lab study only; mixed species; abstract-only |
Key quantitative result: Spectroscopic binding and antiproliferative activity reported; no IC50 or in vivo data visible. External validation: None. Main limitation: In vitro only; no in vivo pharmacokinetics or toxicology. Equity implications: Not applicable at this stage. Evidence Maturity: Exploratory ✓
Article 7 — Gullaksen et al. (2026) — Semaglutide/empagliflozin endothelial function RCT
PMID: 42679726 | RCT (post hoc analysis) | Cardiovascular-Metabolic | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Mechanistic endothelial endpoints add detail to known CV benefit of these agents |
| Clinical Relevance | 6 | T2DM + CV disease is an enormous clinical problem; endothelial function data informs mechanism |
| Population Reach | 8 | T2DM affects ~550 million people globally |
| Implementation Speed | 7 | Both drugs are already in widespread clinical use |
| Evidence Strength | 6 | RCT-derived but post hoc analysis; abstract-only; endpoint details unavailable |
Key quantitative result: Not reported. External validation: Post hoc analysis of existing RCT. Main limitation: Post hoc; may be underpowered for endothelial endpoints; abstract-only. Equity implications: Both drugs are expensive; patients in LMICs have limited access. Evidence Maturity: Validated ✓ (for the parent RCT); post hoc findings remain hypothesis-generating
Article 8 — Moga et al. (2026) — Spleen stiffness in portal vein thrombosis
PMID: 42679862 | Diagnostic Validation Study | Early Detection | 🔴 (misclassified flag)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Extending SSM/VCTE criteria from cirrhosis to non-cirrhotic portal vein thrombosis is genuinely new |
| Clinical Relevance | 7 | Could spare unnecessary endoscopy in a defined, complex patient population |
| Population Reach | 4 | Specific niche: chronic PVT without cirrhosis; moderate-sized population |
| Implementation Speed | 6 | VCTE is widely available; requires institutional protocol change |
| Evidence Strength | 6 | Diagnostic validation design; multicenter author list; abstract-only |
Key quantitative result: SSM ≤40 kPa in cirrhosis rules out HRV; finding challenged in PVT population — endoscopy still required. External validation: Multicenter (European centers implied). Main limitation: Abstract-only; PVT patient numbers likely limited; generalizability uncertain. Equity implications: Non-invasive screening tools reduce burden on patients who lack endoscopy access. Evidence Maturity: Validated ✓
Article 9 — Yajima et al. (2026) — ctDNA time-varying prognosis in urothelial carcinoma
PMID: 42679916 | Meta-analysis | Early Detection | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Time-varying hazard analysis of ctDNA — challenging the standard pooled HR assumption — is methodologically novel |
| Clinical Relevance | 7 | Directly refines how ctDNA results should guide adjuvant therapy and surveillance timing |
| Population Reach | 5 | Urothelial carcinoma: ~600,000 new cases/year globally |
| Implementation Speed | 6 | ctDNA testing increasingly available; methodology requires biostatistical uptake |
| Evidence Strength | 7 | Reconstructed individual patient data meta-analysis is a rigorous design; abstract-only |
Key quantitative result: Challenges proportional hazards assumption for ctDNA prognostic effect — timing of measurement matters. External validation: Multi-source systematic search. Main limitation: Abstract-only; number of included studies and patient totals not reported. Equity implications: ctDNA testing remains expensive and inequitably distributed. Evidence Maturity: Validated ✓
Article 10 — Scott et al. (2026) — Stevia acute endocrine effects RCT
PMID: 42680068 | RCT | Cardiovascular-Metabolic | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Addresses an open question but in a narrow, acute exposure paradigm |
| Clinical Relevance | 4 | Relevant for dietary counseling in T2DM; not practice-changing |
| Population Reach | 6 | Stevia use is widespread; T2DM affects hundreds of millions |
| Implementation Speed | 7 | No regulatory or infrastructure barrier to dietary guidance update |
| Evidence Strength | 6 | RCT design; abstract-only; acute effects only, no long-term data |
Key quantitative result: No significant alteration in endocrine responses — reassuring null finding. External validation: None reported. Main limitation: Acute-only; not informative for long-term metabolic effects. Equity implications: Stevia is widely available across income levels; broadly applicable. Evidence Maturity: Validated ✓
Article 11 — Wang et al. (2026) — CD33 CAR-NK + anti-CD73 for AML
PMID: 42680202 | Lab Study | Treatment Innovation | 🟠
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Dual-function CAR-NK engineering (anti-CD33 + anti-CD73 scFv secretion) to overcome adenosine immunosuppression is a creative and novel design |
| Clinical Relevance | 4 | Preclinical; AML is a high unmet need disease but clinical translation is years away |
| Population Reach | 5 | AML incidence ~20,000/year in US; higher globally; relapsed/refractory has very poor prognosis |
| Implementation Speed | 2 | Preclinical only; manufacturing and safety hurdles substantial |
| Evidence Strength | 4 | Mixed species lab study; abstract-only; no clinical data |
Key quantitative result: Not reported from abstract. External validation: None. Main limitation: Preclinical; mixed species; no in vivo pharmacodynamics or safety data visible. Equity implications: CAR cell therapies are costly and currently accessible only in high-resource centers. Evidence Maturity: Exploratory ✓
Article 12 — Domić et al. (2026) — Vegan diet and muscle mass in older adults RCT
PMID: 42680254 | RCT | Aging/Nutrition | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Randomized comparison of self-selected vegan vs. omnivore vs. vegan+exercise in older adults fills a specific evidence gap |
| Clinical Relevance | 7 | Sarcopenia risk in older adults is clinically important; practical dietary guidance implications |
| Population Reach | 7 | Aging populations worldwide; rising prevalence of plant-based diets |
| Implementation Speed | 8 | Dietary and exercise recommendations can be updated immediately |
| Evidence Strength | 7 | RCT design; 12-week follow-up; abstract-only; full results not visible |
Key quantitative result: Self-selected vegan diet reduces skeletal muscle mass; resistance exercise mitigates this effect. External validation: None reported. Main limitation: 12 weeks may be too short; self-selected diet creates heterogeneity; abstract-only. Equity implications: Plant-based diets more common in lower-income populations globally; findings relevant to a broad audience. Evidence Maturity: Validated ✓
Article 13 — Ward et al. (2026) — PROMED-EX diet+exercise RCT in older adults
PMID: 42680255 | RCT | Aging/Nutrition | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Protein-enriched Mediterranean diet + exercise is a plausible but not entirely novel intervention |
| Clinical Relevance | 7 | Targets undernutrition and cognitive decline in vulnerable older adults |
| Population Reach | 7 | Globally aging population; undernutrition in elderly is widespread |
| Implementation Speed | 7 | Diet and exercise interventions are low-barrier |
| Evidence Strength | 7 | RCT; multicenter (European) author list; abstract-only |
Key quantitative result: Not reported from abstract. External validation: Multicenter European study. Main limitation: Abstract-only; magnitude of cognitive effects and clinical significance unclear. Equity implications: Protein-enriched diet recommendations may not be actionable for food-insecure older adults. Evidence Maturity: Validated ✓
Article 14 — Bawwab et al. (2026) — Normal karyotype fraction prognosis in AML
PMID: 42680613 | Retrospective Cohort (labeled diagnostic validation) | Hematologic Malignancy | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Systematic evaluation of normal karyotype fraction in AML is underexplored and clinically relevant |
| Clinical Relevance | 7 | Could refine AML risk stratification at diagnosis for 893 patients — large single-center cohort |
| Population Reach | 5 | AML is relatively rare but devastating; this finding applicable to all cytogenetically abnormal AML |
| Implementation Speed | 6 | Karyotyping already routine; adding fraction analysis requires minimal infrastructure change |
| Evidence Strength | 6 | Large retrospective cohort (n=893); single center; abstract-only |
Key quantitative result: Not reported from abstract. External validation: Single center (Cleveland Clinic); external validation needed. Main limitation: Retrospective; single center; abstract-only; selection bias possible. Equity implications: Standard cytogenetics widely available; broadly applicable if validated. Evidence Maturity: Validated ✓ (retrospective; prospective confirmation needed)
Article 15 — Arroyo Mühr et al. (2026) — HPV treatment evidence statement
PMID: 42680631 | Systematic Review | Early Detection/Prevention | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Synthesizes existing evidence; refutes unproven treatments rather than introducing new ones |
| Clinical Relevance | 7 | High-impact public health guidance; clarifies what works vs. what doesn't for HPV management |
| Population Reach | 9 | HPV affects ~80% of sexually active individuals; cervical cancer kills 340,000/year globally |
| Implementation Speed | 7 | Society statement format facilitates rapid guideline adoption |
| Evidence Strength | 7 | Systematic review by major professional society (IPVS); abstract-only |
Key quantitative result: Not reported; focus on evidence appraisal. External validation: Synthesizes existing validated trials. Main limitation: Abstract-only; specific conclusions about which treatments are/aren't supported not fully visible. Equity implications: HPV and cervical cancer disproportionately affect women in LMICs; clear guidance on ineffective treatments prevents wasted resources in resource-limited settings. Evidence Maturity: Validated ✓
Article 16 — Ko et al. (2026) — Contrastive learning ECG foundation model
PMID: 42680677 | Diagnostic Validation Study | AI/Diagnostics | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Contrastive learning foundation model for ECG — moving beyond task-specific labels — is a meaningful AI advancement |
| Clinical Relevance | 7 | ECGs are performed billions of times annually; improved AI interpretation has substantial clinical upside |
| Population Reach | 9 | Cardiovascular disease is the leading cause of global mortality; ECG is universal |
| Implementation Speed | 5 | External validation completed; regulatory pathway and EHR integration remain hurdles |
| Evidence Strength | 7 | External validation performed (Lancet Digital Health); abstract-only; performance metrics not available |
Key quantitative result: Not reported from abstract; external validation confirmed. External validation: Yes — explicitly stated in title. Main limitation: Abstract-only; specific AUC/sensitivity/specificity not available; real-world deployment gap remains. Equity implications: ECG is low-cost and globally available; AI interpretation could democratize expert-level ECG reading in underserved settings. Evidence Maturity: Validated ✓
Article 17 — Chen et al. (2026) — CSF cfDNA multi-omic in lung brain mets
PMID: 42676708 | Lab Study | Early Detection | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Nanopore single-molecule multi-omic CSF cfDNA (fragmentation + methylation) is technically innovative |
| Clinical Relevance | 4 | CSF liquid biopsy for brain mets has a clear clinical need but remains early-stage |
| Population Reach | 5 | Lung cancer is common; ~30% develop brain mets; this specific test is a niche application |
| Implementation Speed | 2 | Nanopore CSF sequencing far from routine clinical deployment |
| Evidence Strength | 3 | Small observational lab study; DOI suggests possible 2020 paper (metadata concern); abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Likely small n; DOI/date discrepancy; clinical validation absent. Equity implications: Advanced molecular diagnostics inaccessible in most global settings. Evidence Maturity: Exploratory ✓
Article 18 — Tekin & Gürlek (2026) — Male osteoporosis narrative review
PMID: 42676999 | Narrative Review | Aging | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Largely summarizes existing knowledge on an underrecognized topic |
| Clinical Relevance | 5 | Men with osteoporosis remain underdiagnosed and undertreated; awareness value |
| Population Reach | 6 | Millions of older men globally are affected |
| Implementation Speed | 6 | Recognition and screening changes can be implemented without new tools |
| Evidence Strength | 3 | Narrative review; DOI suggests 2023 paper; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Narrative review; no systematic methods; DOI/date discrepancy. Equity implications: Men in underserved settings are least likely to receive osteoporosis workup. Evidence Maturity: Exploratory ✓
Article 19 — Wang et al. (2026) — SERS microfluidic EV platform for pancreatic cancer
PMID: 42677377 | Diagnostic Validation Study (mixed species) | Early Detection | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Addressing the SERS reproducibility-enhancement trade-off with nanobowl arrays is technically novel |
| Clinical Relevance | 4 | Pancreatic cancer liquid biopsy is a high-need area, but this is early-stage |
| Population Reach | 5 | Pancreatic cancer: ~500,000 new cases/year; devastating prognosis |
| Implementation Speed | 2 | Microfluidic nanobowl platform requires extensive development and validation |
| Evidence Strength | 4 | Diagnostic validation in mixed species context; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Early-stage; mixed species; no clinical cohort validation; manufacturing scalability unknown. Equity implications: Pancreatic cancer survival is uniformly poor globally; early detection would have massive equity impact if validated. Evidence Maturity: Exploratory (revised from Validated)
Article 20 — Adam et al. (2026) — Microbiome in GI cancer narrative review
PMID: 42677508 | Narrative Review | Treatment Innovation | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Microbiome-GI cancer connection is an active area; this review consolidates but does not advance |
| Clinical Relevance | 4 | Conceptual; no actionable clinical tool presented |
| Population Reach | 7 | GI cancers account for ~26% of all cancers globally |
| Implementation Speed | 2 | Microbiome therapeutics in oncology remain largely investigational |
| Evidence Strength | 3 | Narrative review; mixed species; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Narrative; no systematic methods; early-stage field. Equity implications: Gut microbiome is shaped by diet and environment; findings may eventually benefit diverse populations. Evidence Maturity: Exploratory ✓
Article 21 — Sang et al. (2026) — PKM2 methionine sensing in mTORC1
PMID: 42677553 | Lab Study | Aging/Metabolism | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Identifying PKM2 as a direct methionine sensor linking to mTORC1 is a significant mechanistic discovery |
| Clinical Relevance | 3 | Basic science; not yet translatable to clinical practice |
| Population Reach | 4 | Broad relevance to aging, obesity, diabetes, and cancer if translated |
| Implementation Speed | 2 | Years of translational work required |
| Evidence Strength | 4 | Mixed species lab validation; JACS is a high-quality journal; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Preclinical; mixed species; clinical relevance of mTORC1 methionine sensing not yet established. Equity implications: Methionine restriction is a dietary approach with potential broad access, but clinical guidance is years away. Evidence Maturity: Exploratory (revised from Validated)
Article 22 — Catalan et al. (2026) — MSP positive control assays
PMID: 42678053 | Lab Study | Diagnostics | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Standardizing MSP positive controls addresses a real but technical gap |
| Clinical Relevance | 5 | Improves reliability of widely used cancer diagnostic methylation assays |
| Population Reach | 5 | MSP is broadly used in cancer diagnostics globally |
| Implementation Speed | 6 | Protocol change in existing labs; relatively low barrier |
| Evidence Strength | 4 | Lab study; unknown species; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Unknown species/context; highly technical; impact depends on laboratory adoption. Equity implications: Improved standardization benefits all labs; particularly valuable in resource-limited settings where assay reliability is harder to monitor. Evidence Maturity: Exploratory ✓
Article 23 — Reilly et al. (2025) — Lower extremity amputation trends cohort
PMID: 42678519 | Cohort Study | Population Health | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Trend analysis in a single US state; informative but not groundbreaking |
| Clinical Relevance | 6 | Amputation in DM/PAD is a major preventable outcome; trend data informs policy |
| Population Reach | 7 | Diabetes-related amputation is a global public health crisis |
| Implementation Speed | 5 | Policy implications but no direct clinical intervention |
| Evidence Strength | 5 | Cohort with administrative data; Illinois-specific; abstract-only |
Key quantitative result: Not reported. External validation: None (single-state). Main limitation: Geographic limitation; administrative data may lack clinical granularity. Equity implications: Amputation rates are highly disparate by race and socioeconomic status; trend data essential for equity-focused interventions. 🟡 Evidence Maturity: Exploratory ✓
Article 24 — Li et al. (2026) — AML1-ETO glutathione metabolism in LSCs
PMID: 42679037 | Lab Study | Treatment Innovation | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | AML1-ETO recruiting to distal enhancer of NAT10 to reprogram glutathione in LSCs is mechanistically novel |
| Clinical Relevance | 3 | Preclinical; identifies potential therapeutic target in t(8;21) AML |
| Population Reach | 4 | t(8;21) AML is a defined subset (~7% of AML); modest but real unmet need |
| Implementation Speed | 2 | Basic science discovery; years from therapeutic application |
| Evidence Strength | 4 | Mixed species; PNAS is high-quality venue; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Preclinical; mixed species; mechanism-to-drug development gap is large. Equity implications: AML outcomes are worse in underserved populations; mechanistic insights benefit future drug development. Evidence Maturity: Exploratory ✓
Article 25 — Vilaplana et al. (2026) — SEHOP-PENCIL pediatric precision oncology
PMID: 42679328 | Multicenter Observational | Diagnostics | 🟢
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | National program implementation rather than scientific discovery |
| Clinical Relevance | 7 | Expanding genomic sequencing access for pediatric cancer across Spain is directly impactful |
| Population Reach | 5 | Spain's pediatric cancer population; model applicable to other countries |
| Implementation Speed | 6 | Infrastructure already being built; results guide further rollout |
| Evidence Strength | 5 | Observational; survey-based; multicenter; abstract-only |
Key quantitative result: Improved access to genomic sequencing reported; specific numbers not available from abstract. External validation: Multicenter national program. Main limitation: Survey-based; abstract-only; outcomes data pending. Equity implications: Directly addresses inequity in access to precision oncology for children across different Spanish hospital settings. 🟡 Evidence Maturity: Exploratory ✓
Article 26 — Teramoto et al. (2026) — Haploidentical vs. cord blood transplant in AML with MRD
PMID: 42679593 | Cohort Study | Hematologic Malignancy | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Comparative effectiveness of PTCy-haplo vs. uCBT in MRD-positive AML is clinically relevant and understudied |
| Clinical Relevance | 7 | Guides transplant selection for a high-risk patient subgroup |
| Population Reach | 4 | AML requiring alternative donor transplant; niche but high unmet need |
| Implementation Speed | 5 | Both transplant types already in clinical use; findings could shift practice |
| Evidence Strength | 5 | Retrospective cohort; likely registry-based; abstract-only |
Key quantitative result: Not reported. External validation: Registry-based Japanese data implied. Main limitation: Retrospective; likely confounded by center effects and patient selection; abstract-only. Equity implications: Cord blood and haploidentical transplants expand access for patients without matched donors, including minority populations underrepresented in registries. 🟡 Evidence Maturity: Exploratory ✓
Article 27 — Khalil et al. (2026) — ESR1 electrochemical biosensor for breast cancer
PMID: 42679736 | Lab Study | Early Detection | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Label-/enzyme-free electrochemical biosensor for ESR1 detection in liquid biopsy is technically innovative |
| Clinical Relevance | 3 | Preclinical; ESR1 is a validated target but the sensor requires clinical validation |
| Population Reach | 7 | Breast cancer is the most common cancer in women globally |
| Implementation Speed | 2 | Early-stage; regulatory and manufacturing path required |
| Evidence Strength | 3 | Lab study; abstract-only; no clinical samples reported |
Key quantitative result: Not reported. External validation: None. Main limitation: Lab-only; no clinical validation; sensor performance in heterogeneous biological samples unknown. Equity implications: If low-cost and validated, could extend prognostic testing to LMICs. Evidence Maturity: Exploratory ✓
Article 28 — Chaddad et al. (2026) — 3D-FuseNet brain tumor survival prediction
PMID: 42679753 | Lab Study | AI/Diagnostics | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Multimodal 3D imaging + clinical data fusion for survival prediction is a meaningful contribution |
| Clinical Relevance | 4 | Brain tumor prognosis is clinically important; requires prospective validation |
| Population Reach | 4 | Brain tumors: ~300,000 new cases/year globally |
| Implementation Speed | 3 | Requires clinical validation and integration into radiology workflows |
| Evidence Strength | 4 | Retrospective lab study; abstract-only; likely TCGA/public dataset |
Key quantitative result: Not reported. External validation: None reported. Main limitation: Likely trained/tested on public datasets; prospective real-world validation absent. Equity implications: Advanced imaging AI requires high-resolution MRI infrastructure, which is inequitably distributed. Evidence Maturity: Exploratory ✓
Article 29 — Li et al. (2026) — CRISPR-Cas12a single-base mutation detection
PMID: 42679775 | Lab Study | Early Detection | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | crRNA-universal CRISPR-Cas12a system addressing specificity AND sensitivity for low-abundance mutations is technically significant |
| Clinical Relevance | 4 | Liquid biopsy application is clear, but clinical validation is absent |
| Population Reach | 6 | Broad cancer liquid biopsy application if validated |
| Implementation Speed | 3 | CRISPR diagnostics require extensive clinical validation pathway |
| Evidence Strength | 3 | Unknown species context; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: No clinical samples; species unknown; performance in complex matrices not reported. Equity implications: CRISPR diagnostics could eventually be low-cost point-of-care tools. Evidence Maturity: Exploratory (revised from Validated)
Article 30 — Nishimura et al. (2026) — Castleman disease management paradigms
PMID: 42679859 | Review | Treatment Innovation | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Castleman disease management has evolved substantially; synthesis in JNCCN is valuable |
| Clinical Relevance | 7 | Rare disease with high unmet need; updated guidance directly affects patient care |
| Population Reach | 3 | Very rare (estimated 5,000–6,000 cases/year in US) |
| Implementation Speed | 6 | Review translates directly into clinical practice guidelines |
| Evidence Strength | 5 | Expert review in JNCCN; abstract-only; design labeled "diagnostic validation" incorrectly |
Key quantitative result: Not reported. External validation: Synthesizes existing literature. Main limitation: Review only; abstract-only; metadata mislabeled. Equity implications: Rare disease recognition and access to siltuximab/rituximab therapy is highly inequitable globally. Evidence Maturity: Validated ✓ (for existing evidence synthesized)
Article 31 — Yu et al. (2026) — Deep learning lung function from CBCT for adaptive RT
PMID: 42679907 | Diagnostic Validation | AI/RT | 🟢
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Deriving lung function maps from on-board CBCT (avoiding extra scans) is a clinically smart approach |
| Clinical Relevance | 6 | Functional avoidance in adaptive RT could reduce radiation-induced lung toxicity |
| Population Reach | 5 | Lung cancer RT patients; ~2 million new lung cancer cases/year globally |
| Implementation Speed | 5 | CBCT is standard in RT units; software-level integration feasible |
| Evidence Strength | 5 | Diagnostic validation; abstract-only; performance metrics unavailable |
Key quantitative result: Not reported. External validation: None confirmed. Main limitation: Abstract-only; clinical impact on pulmonary toxicity outcomes not yet demonstrated. Equity implications: RT is increasingly available in LMICs; this AI tool could optimize treatment without additional imaging costs. Evidence Maturity: Validated ✓ (technical validation stage)
Article 32 — Wang et al. (2026) — Patient-derived organoids for hepatobiliary cancer
PMID: 42679918 | Narrative Review | Precision Oncology | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | PDOs are an established and growing platform; this review consolidates their role in hepatobiliary cancers |
| Clinical Relevance | 5 | Drug selection guidance for a cancer with high drug resistance and poor prognosis |
| Population Reach | 6 | Liver/biliary cancers: ~1 million new cases/year globally |
| Implementation Speed | 3 | PDO infrastructure is complex and not widely available |
| Evidence Strength | 3 | Narrative review; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Narrative; no primary data; PDO implementation remains logistically complex. Equity implications: PDO-guided therapy currently accessible only in advanced academic centers. Evidence Maturity: Exploratory ✓
Article 33 — Echeverría et al. (2026) — HFrEF quadruple therapy in Latin America
PMID: 42679954 | Cohort Study | Cardiovascular | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Real-world GDMT adherence data from Latin America fills a geographic evidence gap |
| Clinical Relevance | 7 | Guideline adherence in HFrEF has direct mortality impact |
| Population Reach | 7 | Heart failure affects ~64 million people globally; Latin America is underrepresented in registries |
| Implementation Speed | 6 | Implementation science — gap between guidelines and practice |
| Evidence Strength | 5 | Retrospective cohort; single-region; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Retrospective; single-region; may not generalize beyond Latin America. Equity implications: Explicitly addresses underserved Latin American populations with HFrEF. 🟡 Evidence Maturity: Exploratory ✓
Article 34 — Qin et al. (2026) — Senescence biomarkers and anti-aging therapy review
PMID: 42680071 | Review | Aging | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Synthesizes a rapidly evolving field; senolytics and senomorphics are active areas |
| Clinical Relevance | 4 | No specific validated clinical intervention presented |
| Population Reach | 8 | Aging-related disease affects everyone; universal relevance |
| Implementation Speed | 2 | Anti-aging therapies remain largely investigational |
| Evidence Strength | 3 | Review; mislabeled as "diagnostic validation"; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Review only; no primary data; field is promising but few approved interventions exist. Equity implications: Anti-aging therapies, if effective, currently benefit wealthier populations disproportionately. Evidence Maturity: Exploratory ✓
Article 35 — Berggreen et al. (2026) — AI calibration framework for ultrasound nerve segmentation
PMID: 42680190 | Diagnostic Validation | AI/Procedural | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Multi-rater consensus framework for AI medical image validation is a methodological contribution |
| Clinical Relevance | 5 | Nerve block guidance accuracy has patient safety implications; important but niche |
| Population Reach | 4 | Regional anesthesia is common; but the specific application is narrow |
| Implementation Speed | 5 | Framework is immediately applicable to AI validation studies |
| Evidence Strength | 6 | Nine-clinician multi-rater design; Anaesthesia is a reputable journal; abstract-only |
Key quantitative result: Not reported. External validation: Not applicable (framework development study). Main limitation: Abstract-only; clinical impact of the framework not yet demonstrated. Equity implications: Better AI validation frameworks benefit all patients who receive AI-guided procedures. Evidence Maturity: Validated ✓ (methodological)
Article 36 — Shuai et al. (2026) — Long-read sequencing novel splicing in nasopharyngeal carcinoma
PMID: 42680560 | Cohort Study | Precision Oncology | ⚪
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Comprehensive AS landscape in NPC using long-read sequencing, revealing immunotherapy neoantigen targets, is a meaningful advance |
| Clinical Relevance | 4 | Preclinical discovery; personalized neoantigen vaccine development required |
| Population Reach | 4 | NPC is rare globally but endemic in Southeast Asia and China; regional unmet need |
| Implementation Speed | 2 | Neoantigen vaccine development is years away |
| Evidence Strength | 5 | Cohort with long-read sequencing; Genome Research is a strong venue; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Discovery-stage; no clinical or immunological validation. Equity implications: NPC disproportionately affects East/Southeast Asian populations — findings are regionally relevant. Evidence Maturity: Exploratory ✓
Article 37 — Omari et al. (2026) — 3D-printed temporal bone RCT in cochlear implantation
PMID: 42680684 | RCT | Diagnostics/Surgical | 🟢
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Patient-specific 3D-printed surgical models tested in an RCT is notable; evidence base for this technology is growing |
| Clinical Relevance | 5 | Surgeon cognitive load reduction is a meaningful safety outcome; limited direct patient outcome data visible |
| Population Reach | 4 | Cochlear implantation: ~70,000 procedures/year globally |
| Implementation Speed | 6 | 3D printing is increasingly accessible to surgical centers |
| Evidence Strength | 7 | RCT (n=40); 12 surgeons; randomized design; abstract-only |
Key quantitative result: 40 consecutive adult primary CI surgeries; cognitive load assessed. External validation: None. Main limitation: Small n (40); subjective cognitive load outcome; clinical outcome data (complications, operating time) not reported from abstract. Equity implications: 3D printing infrastructure not available in most low-resource settings where hearing device access is already limited. Evidence Maturity: Validated ✓
Article 38 — Rani et al. (2026) — Extracellular vesicle lipid profiles for ovarian cancer
PMID: 42680694 | Cohort Study | Early Detection | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Combining sEV + total lipid profiles to outperform CA-125 across ovarian cancer subtypes — including borderline and low-grade — is a meaningful diagnostic advance |
| Clinical Relevance | 7 | CA-125 misses a substantial proportion of early and borderline ovarian cancers; improving on this standard has direct clinical relevance |
| Population Reach | 6 | Ovarian cancer: ~315,000 new cases/year; 5-year survival ~49% overall, much worse at late stage |
| Implementation Speed | 3 | Requires clinical validation and regulatory approval; lipidome profiling is not routine |
| Evidence Strength | 5 | Cohort design; multi-subtype analysis; abstract-only |
Key quantitative result: Not reported; diagnostic advantage over CA-125 claimed. External validation: None reported. Main limitation: Abstract-only; cohort size unknown; lipidomics not yet clinically deployable; overfitting risk in biomarker discovery studies. Equity implications: Ovarian cancer has poor survival in LMICs where late-stage diagnosis is nearly universal; better early detection tools are urgently needed. Evidence Maturity: Exploratory (revised from Validated — biomarker discovery cohort)
Article 39 — Barton et al. (2026) — GLP-1 RAs in total joint arthroplasty
PMID: 42678766 | Narrative Review | Cardiovascular-Metabolic/Surgery | ⬜
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Clinically timely; GLP-1 perioperative management is a genuinely new practical problem |
| Clinical Relevance | 6 | Many surgical patients are now on GLP-1 RAs; perioperative guidance is urgently needed |
| Population Reach | 7 | Millions on GLP-1 RAs; total joint arthroplasty is one of the most common elective surgeries |
| Implementation Speed | 6 | Anesthesia/surgical protocols can be adjusted rapidly based on review guidance |
| Evidence Strength | 3 | Narrative review; abstract-only |
Key quantitative result: Not reported. External validation: None. Main limitation: Narrative; no systematic methods; primary evidence base for this specific question remains sparse. Equity implications: GLP-1 RA use is rising across income levels; perioperative guidance broadly applicable. Evidence Maturity: Exploratory ✓
Article 40 — Kadesjö et al. (2026) — SGLT2 inhibitor ketoacidosis Scandinavian cohort
PMID: 42679839 | Cohort + Nested Case-Control | Cardiovascular-Metabolic | ⬜
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Large real-world data on SGLT2i ketoacidosis incidence, risk factors, and prognosis fills an evidence gap |
| Clinical Relevance | 7 | SGLT2i are widely prescribed; DKA risk is a known but poorly quantified concern in clinical practice |
| Population Reach | 8 | SGLT2i used by tens of millions globally with T2DM |
| Implementation Speed | 7 | Findings can immediately inform prescribing and monitoring guidelines |
| Evidence Strength | 7 | Nationwide Scandinavian registry; robust nested case-control design; Lancet Diabetes & Endocrinology; abstract-only |
Key quantitative result: Not reported; incidence, risk factors, and prognosis of ketoacidosis assessed. External validation: Multinational Scandinavian registry (Norway, Sweden, Denmark implied). Main limitation: Abstract-only; Scandinavian population may not generalize to more diverse T2DM populations. Equity implications: SGLT2i DKA risk may affect patients with variable monitoring access; safety signals matter most in under-resourced settings. Evidence Maturity: Validated ✓
Article 41 — Shi et al. (2026) — Annular repair with all-suture anchor under biportal endoscopy
PMID: 42680683 | Case Series | Surgical Innovation | ⬜
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Technical innovation for endoscopic annular repair of difficult-access defects |
| Clinical Relevance | 5 | Addresses a real surgical problem (re-herniation after discectomy) |
| Population Reach | 5 | Lumbar disc disease is extremely common globally |
| Implementation Speed | 4 | Requires specialized endoscopic training and equipment |
| Evidence Strength | 3 | Case series; abstract-only; no controlled comparison |
Key quantitative result: Early clinical outcomes assessed; specific data not available from abstract. External validation: None. Main limitation: Case series; no control group; short-term outcomes only. Equity implications: Minimally invasive alternatives to open surgery could benefit patients in systems that lack infrastructure for complex open spine procedures. Evidence Maturity: Validated ✓ (technical feasibility stage only)
Article 42 — Hai et al. (2026) — Kinome screening in PDAC
PMID: 42680696 | In vitro Study | Preclinical Oncology | 🔴
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Genotype-informed whole-animal kinome screening in multiple PDAC driver contexts is a sophisticated and novel approach |
| Clinical Relevance | 2 | Entirely preclinical; in vitro/Drosophila model; no human data |
| Population Reach | 5 | PDAC: one of the deadliest cancers; ~500,000 deaths/year globally |
| Implementation Speed | 1 | Years from any clinical application |
| Evidence Strength | 3 | In vitro; non-human model; abstract-only |
Key quantitative result: Shared kinase vulnerabilities across driver contexts identified. External validation: None. Main limitation: Non-human model; in vitro; no pharmacological validation. Equity implications: PDAC prognosis is equally poor across all populations; drug targets identified here could eventually benefit all patients. Evidence Maturity: Exploratory ✓
Article 43 — Yaringaño et al. (2026) — ctDNA mutant allele frequency in EGFR rechallenge CRC
PMID: 42679330 | Observational Study | Early Detection | 🔴
⚠️ LOW CONFIDENCE — title only; no abstract available
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ctDNA-guided anti-EGFR rechallenge is an active and clinically relevant area in mCRC |
| Clinical Relevance | 6 | If validated, guides retreatment decisions in a common cancer |
| Population Reach | 6 | Colorectal cancer: ~1.9 million new cases/year globally |
| Implementation Speed | 4 | ctDNA testing for treatment guidance is emerging but not standardized |
| Evidence Strength | 2 | Title only; no abstract; unknown species; low classification confidence — all scores heavily capped |
Key quantitative result: Not available. External validation: Not assessable. Main limitation: No abstract; all scoring is speculative based on title. Equity implications: ctDNA-guided therapy is currently available only in well-resourced oncology centers. Evidence Maturity: Cannot assess — Watchlist only
Article 44 — [Reilly et al. (2025) — duplicate check]
(Already assessed as Article 23 — PMID 42678519)
Metadata quality note for the full batch: Multiple articles contain DOI mismatches (Articles 1, 4, 17, 18 appear to have DOIs resolving to papers from 2019–2023 rather than 2026), study design mislabelings (Article 2 labeled RCT when it is a review; Articles 30, 34 mislabeled), and species inconsistencies. These reduce confidence in the automated Phase 1 outputs and are reflected in conservative Phase 2 scoring.